Press Release<< Back
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
Low-Grade Serous Ovarian Cancer (LGSOC) is a Unique and Distinct Ovarian Cancer, Requiring Tailored Resources and Management Approach for Patients
Initiative Developed with Input from Patients, Advocates and Physicians Provides Information and Support
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005022/en/
(Graphic: Business Wire)
LGSOC is a rare form of ovarian cancer that commonly affects younger women with a median age at diagnosis between 45-551, and for many, the disease and its treatment will have a long-lasting impact on mental and physical health, including fertility and early menopause.2,3,4 Limited treatment options are available for LGSOC and no treatments specifically for LGSOC have been approved to date.5
“When I was diagnosed with LGSOC, it would have been immensely helpful to have specific information and discussion about the disease that I could relate to,” said
LGSOC has only recently been classified as a separate disease as compared to the more common high grade serous ovarian cancer (HGSOC) with different epidemiology, pathology, clinical presentation and outcomes.6 LGSOC is primarily driven by the RAS pathway, which is a key regulator of several aspects of normal cell growth and malignant transformation, and present in a third of all cancers, including LGSOC.1,7 LGSOC is a serious disease that is likely to be diagnosed when it has already spread outside of the ovaries.8 It is relatively resistant to chemotherapy and highly recurrent.1,9 Eighty-five percent of people with LGSOC will have their cancer come back after remission.9 LGSOC represents 6-8% of all ovarian cancers.1
“Low-grade serous ovarian cancer is a distinct and under-investigated disease that warrants dedicated research and education,” said
“Since my LGSOC diagnosis, I have made raising awareness of symptoms and improving outcomes for LGSOC survivors my mission,” said
For more information about Let’s Talk About LGSOC, please visit LetsTalkAboutLGSOC.com.
About Low-Grade Serous Ovarian Cancer (LGSOC)
Low-grade serous ovarian cancer (LGSOC) is a highly recurrent, chemotherapy-resistant cancer, associated with slow tumor growth and high mortality rate. Approximately 6,000 women in the
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
1 Grisham, R. Low Grade Serous Carcinoma of the Ovary. Oncology. 2016. 30(7):650-652. https://www.cancernetwork.com/view/low-grade-serous-carcinoma-ovary. Accessed
2 Key Statistics for Ovarian Cancer.
3 Norton, Tina R. Ovarian Cancer Patients' Psychological Distress: The Role of Physical Impairment, Perceived Unsupportive Family and Friend Behaviors, Perceived Control, and Self-Esteem. APA PsycNet. https://psycnet.apa.org/record/2005-02260-003. Accessed
4 Social & Emotional Impacts of Cancer.
5 Ovarian Cancer Guidelines. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed
6 Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO Classification of Tumors of Female Reproductive Organs, 4th ed; 2014.
8 Findlay et al. The Ovary (Third Edition). 2019. Pages 1-3.
9 Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing Treatment in Recurrent Epithelial Ovarian Cancer. Expert Rev Anticancer Ther. 2017; 17:1147-1158. doi: 10.1080/14737140.2017.1398088.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005022/en/
+1 (781) 292-4205
Source: Verastem Oncology